Suppr超能文献

肺癌化疗与免疫疗法的今昔

The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy.

作者信息

Visconti Roberta, Morra Francesco, Guggino Gianluca, Celetti Angela

机构信息

Institute for the Experimental Endocrinology and Oncology "G. Salvatore", Italian National Council of Research, via S. Pansini 5, 80131 Napoli, Italy.

Thoracic Surgery Unit, Antonio Cardarelli Hospital, via A. Cardarelli 9, 80131 Napoli, Italy.

出版信息

Int J Mol Sci. 2017 Jun 27;18(7):1374. doi: 10.3390/ijms18071374.

Abstract

Lung cancer is the most common cancer worldwide. Disappointingly, despite great effort in encouraging screening or, at least, a close surveillance of high-risk individuals, most of lung cancers are diagnosed when already surgically unresectable because of local advancement or metastasis. In these cases, the treatment of choice is chemotherapy, alone or in combination with radiotherapy. Here, we will briefly review the most successful and recent advances in the identification of novel lung cancer genetic lesions and in the development of new drugs specifically targeting them. However, lung cancer is still the leading cause of cancer-related mortality also because, despite impressive initial responses, the patients often develop resistance to novel target therapies after a few months of treatment. Thus, it is literally vital to continue the search for new therapeutic options. So, here, on the basis of our recent findings on the role of the tumor suppressor CCDC6 protein in lung tumorigenesis, we will also discuss novel therapeutic approaches we envision for lung cancer.

摘要

肺癌是全球最常见的癌症。令人失望的是,尽管在鼓励筛查或至少密切监测高危个体方面付出了巨大努力,但大多数肺癌在因局部进展或转移而无法手术切除时才被诊断出来。在这些情况下,首选的治疗方法是化疗,单独使用或与放疗联合使用。在这里,我们将简要回顾在鉴定新型肺癌基因损伤以及开发专门针对这些损伤的新药方面最成功和最新的进展。然而,肺癌仍然是癌症相关死亡的主要原因,这也是因为尽管最初反应令人印象深刻,但患者在治疗几个月后往往会对新型靶向治疗产生耐药性。因此,继续寻找新的治疗选择确实至关重要。所以,在此,基于我们最近关于肿瘤抑制因子CCDC6蛋白在肺癌发生中的作用的研究结果,我们还将讨论我们设想的针对肺癌的新型治疗方法。

相似文献

1
The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy.
Int J Mol Sci. 2017 Jun 27;18(7):1374. doi: 10.3390/ijms18071374.
3
Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy.
Curr Drug Targets. 2015;16(13):1448-63. doi: 10.2174/1389450115666140528151649.
4
[Lung cancer : What has been confirmed in therapy?].
Internist (Berl). 2017 Dec;58(12):1258-1263. doi: 10.1007/s00108-017-0339-4.
6
[Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Klin Onkol. 2016 Fall;29 Suppl 4(Suppl 4):78-87.
7
The evolving locally-advanced non-small cell lung cancer landscape: Building on past evidence and experience.
Crit Rev Oncol Hematol. 2015 Nov;96(2):319-27. doi: 10.1016/j.critrevonc.2015.05.020. Epub 2015 Jun 7.
8
Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?
Cancer Metastasis Rev. 2015 Mar;34(1):129-44. doi: 10.1007/s10555-015-9550-8.
9
Immunotherapy for lung cancer: for whom the bell tolls?
Tumour Biol. 2015 Mar;36(3):1411-22. doi: 10.1007/s13277-015-3285-6. Epub 2015 Mar 4.
10
Evolving Treatment Options for Lung Cancer.
Hematol Oncol Clin North Am. 2017 Feb;31(1):xiii-xiv. doi: 10.1016/j.hoc.2016.09.001.

引用本文的文献

1
Characterization of the immune cell infiltration patterns in lung adenocarcinoma to facilitate immunotherapy.
Heliyon. 2025 Feb 15;11(4):e42720. doi: 10.1016/j.heliyon.2025.e42720. eCollection 2025 Feb 28.
3
Does needle gauge affect complication rates of computed tomography-guided lung biopsy?
J Thorac Dis. 2024 Jul 30;16(7):4310-4318. doi: 10.21037/jtd-24-240. Epub 2024 Jul 16.
4
The Effect of MiR320a on Lung Cancer.
Microrna. 2024;13(3):167-174. doi: 10.2174/0122115366296148240530072346.
6
Investigating the role of let-7a microRNA in cisplatin sensitivity of A549 lung cancer cells.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jun;397(6):3979-3984. doi: 10.1007/s00210-023-02858-y. Epub 2023 Nov 22.
9
Genistein-induced mitochondrial dysfunction and FOXO3a/PUMA expression in non-small lung cancer cells.
Pharm Biol. 2022 Dec;60(1):1876-1883. doi: 10.1080/13880209.2022.2123933.

本文引用的文献

2
T cell exhaustion: from pathophysiological basics to tumor immunotherapy.
Cell Commun Signal. 2017 Jan 5;15(1):1. doi: 10.1186/s12964-016-0160-z.
3
Cancer Statistics, 2017.
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
6
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8.
8
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
9
USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.
Lung Cancer. 2017 May;107:41-49. doi: 10.1016/j.lungcan.2016.06.015. Epub 2016 Jun 17.
10
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.
Front Oncol. 2016 May 4;6:112. doi: 10.3389/fonc.2016.00112. eCollection 2016.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验